{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TP2", "query": { "intervention": "TP2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TP2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T16:25:30.204Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03491683", "title": "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "INO-5401", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2018-05-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 21, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03491683" }, { "nct_id": "NCT03265717", "title": "DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "INVAC-1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Invectys", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-07-25", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-08", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03265717" }, { "nct_id": "NCT05428774", "title": "Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fluid Retention", "Beverage Hydration Index", "Hydration Status" ], "interventions": [ { "name": "Test product 1", "type": "OTHER" }, { "name": "Test product 2", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Liquid I.V.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 15, "start_date": "2022-08-01", "completion_date": "2023-01-01", "has_results": false, "last_update_posted_date": "2023-01-25", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428774" }, { "nct_id": "NCT06293365", "title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjögrens Disease", "Systemic Lupus Erythematosus", "Rheumatoid Arthritis" ], "interventions": [ { "name": "VAY736 1ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2 ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2ml AI", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 155, "start_date": "2024-07-02", "completion_date": "2029-01-16", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 17, "location_summary": "Anniston, Alabama • Fullerton, California • La Palma, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293365" }, { "nct_id": "NCT02277106", "title": "Evaluate SAGE-547 in Participants With Essential Tremor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Essential Tremor" ], "interventions": [ { "name": "SAGE-547", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sage Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 25, "start_date": "2014-09-23", "completion_date": "2015-08-14", "has_results": true, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 2, "location_summary": "Bingham Farms, Michigan • Raleigh, North Carolina", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277106" }, { "nct_id": "NCT03502785", "title": "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "INO-5401", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-07-24", "completion_date": "2025-05-09", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502785" }, { "nct_id": "NCT05428761", "title": "Clinical Trial to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dehydration", "Rehydration", "Exercise Performance", "Exercise Recovery", "Fluid Balance", "Cognitive Performance" ], "interventions": [ { "name": "TP1", "type": "OTHER" }, { "name": "TP2", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Liquid I.V.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 16, "start_date": "2022-08-01", "completion_date": "2023-01-01", "has_results": false, "last_update_posted_date": "2023-01-25", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 1, "location_summary": "Columbia, South Carolina", "locations": [ { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428761" }, { "nct_id": "NCT04300296", "title": "PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris" ], "interventions": [ { "name": "secukinumab 300 mg Q4W", "type": "DRUG" }, { "name": "secukinumab 300 mg Q2W", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2020-07-27", "completion_date": "2022-05-03", "has_results": true, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300296" }, { "nct_id": "NCT02960594", "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "Ovarian Cancer", "ColoRectal Cancer", "Gastric Cancer", "Esophageal Cancer", "HepatoCellular Carcinoma" ], "interventions": [ { "name": "INO-1400", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "INO-1401", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2014-12", "completion_date": "2018-11-09", "has_results": false, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 6, "location_summary": "Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02960594" }, { "nct_id": "NCT05428228", "title": "Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dehydration", "Rehydration", "Exercise Performance", "Exercise Recovery", "Cognitive Performance" ], "interventions": [ { "name": "TP1", "type": "OTHER" }, { "name": "TP2", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Liquid I.V.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 16, "start_date": "2022-10-01", "completion_date": "2024-09-01", "has_results": false, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-09-08T16:25:30.204Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428228" } ] }